Evaluation of the dual peroxisome proliferator-activated receptor [alpha]/[gamma] agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial.

Autor: Lincoff, A Michael, Tardif, Jean-Claude, Neal, Bruce, Nicholls, Stephen J, Rydén, Lars, Schwartz, Gregory G, Malmberg, Klas, Buse, John B, Henry, Robert R, Wedel, Hans, Weichert, Arlette, Cannata, Ruth, Grobbee, Diederick E
Zdroj: American Heart Journal; Sep2013, Vol. 166 Issue 3, p429-434.e1, 1p
Databáze: Supplemental Index
Externí odkaz: